Bioatla hosting virtual r&d day to highlight ba3071 cab-ctla-4 phase 1 data in multiple solid tumor types

Multiple confirmed responses and durable disease control observed emerging differentiated safety profile enables further exploration at higher doses ongoing phase 2 clinical study of monotherapy and in combination with a pd-1 inhibitor san diego, dec. 13, 2023 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today is hosting a virtual r&d day on its novel conditionally and reversibly active antibody targeting ctla-4, ba3071. ba3071 is in phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to ctla-4 treatment as monotherapy, and in combination with a pd-1 blocking agent.
BCAB Ratings Summary
BCAB Quant Ranking